These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10155093)

  • 21. Minimally invasive bypass surgery.
    Dragu RE
    N Engl J Med; 2002 Dec; 347(26):2165-8; author reply 2165-8. PubMed ID: 12501850
    [No Abstract]   [Full Text] [Related]  

  • 22. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
    Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
    N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.
    Exaire JE; Lincoff AM
    J Thromb Haemost; 2004 Jan; 2(1):7-9. PubMed ID: 14717958
    [No Abstract]   [Full Text] [Related]  

  • 25. Interventional therapy for coronary artery disease.
    Shah PB; Lilly CM
    Am J Respir Crit Care Med; 2002 Sep; 166(6):791-6. PubMed ID: 12231486
    [No Abstract]   [Full Text] [Related]  

  • 26. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Readministration of abciximab in percutaneous coronary intervention.
    Fry ET
    J Invasive Cardiol; 1999 Apr; 11(4):251-8. PubMed ID: 10745525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty.
    Mazurov AV; Pevzner DV; Antonova OA; Byzova TV; Khaspekova SG; Semenov AV; Vlasik TN; Samko AN; Staroverov II; Ruda MY
    Platelets; 2002 Dec; 13(8):465-77. PubMed ID: 12487780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of abciximab in coronary angioplasty--an Asian centre's experience.
    Tan HC; Lim YT; Lim TT; Cheng A; Chia BL
    Singapore Med J; 2000 Feb; 41(2):69-73. PubMed ID: 11063206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies].
    Internist (Berl); 1998 Dec; 39(12 Suppl Plattchena):1-4. PubMed ID: 10101692
    [No Abstract]   [Full Text] [Related]  

  • 31. Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience.
    Patel SS; Rana H; Mascarenhas DA
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):89-93. PubMed ID: 18413897
    [TBL] [Abstract][Full Text] [Related]  

  • 32. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials.
    van de Werf F
    Eur Heart J; 1996 Mar; 17(3):325-6. PubMed ID: 8737200
    [No Abstract]   [Full Text] [Related]  

  • 33. Routine use of abciximab in coronary stenting?
    Stables RH
    Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267
    [No Abstract]   [Full Text] [Related]  

  • 34. Future trials of antiplatelet agents in cardiac ischemia.
    Throckmorton DC
    N Engl J Med; 2001 Jun; 344(25):1937-9. PubMed ID: 11419432
    [No Abstract]   [Full Text] [Related]  

  • 35. A retrospective study of the management of retro-peritoneal bleeding after percutaneous coronary intervention in the era of combination anti-platelet therapy.
    Foley P
    J Cardiovasc Med (Hagerstown); 2008 Jan; 9(1):56-8. PubMed ID: 18268420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of glycoprotein IIb/IIIa inhibitors during elective coronary revascularization: a meta-analysis of randomized trials performed in the era of stents and thienopyridines.
    Winchester DE; Wen X; Brearley WD; Park KE; Anderson RD; Bavry AA
    J Am Coll Cardiol; 2011 Mar; 57(10):1190-9. PubMed ID: 21371635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiplatelet therapy for ischemic heart disease.
    Lange RA; Hillis LD
    N Engl J Med; 2004 Jan; 350(3):277-80. PubMed ID: 14724308
    [No Abstract]   [Full Text] [Related]  

  • 39. Glycoprotein Wars and PIECE activists.
    Goldberg S
    J Invasive Cardiol; 2003 Jun; 15(6):324-5. PubMed ID: 12777671
    [No Abstract]   [Full Text] [Related]  

  • 40. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
    Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.